Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective To systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms.Methods The Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model.Results Overall, five studies were included, revealing that psilocybin was superior to the placebo in treating state anxiety at 1 day (Hedges’ g, -0.70; 95% confidence interval, -1.01 to -0.39) and 2 weeks (-1.03; -1.47 to -0.60) after treatment. Psilocybin was more effective than placebo in treating trait anxiety at 1 day (-0.71; -1.15 to -0.26), 2 weeks (-1.08; -1.80 to -0.36), and 6 months (-0.84; -1.37 to -0.30) after treatment. Psilocybin was associated with transient elevation in systolic (19.00; 13.58–24.41 mm Hg) and diastolic (8.66; 5.18–12.15 mm Hg) blood pressure compared with placebo. The differences between psilocybin and placebo groups with regard to allcause discontinuation, serious adverse events, and heart rates were nonsignificant.Conclusion Psilocybin-assisted therapy could ameliorate end-of-life anxiety symptoms without serious adverse events. Because of the small sample sizes of the included studies and high heterogeneity on long-term outcomes, future randomized controlled trials with large sample sizes are needed.
Abstract
Objective To systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms.Methods The Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model.Results Overall, five studies were included, revealing that psilocybin was superior to the placebo in treating state anxiety at 1 day (Hedges’ g, -0.70; 95% confidence interval, -1.01 to -0.39) and 2 weeks (-1.03; -1.47 to -0.60) after treatment. Psilocybin was more effective than placebo in treating trait anxiety at 1 day (-0.71; -1.15 to -0.26), 2 weeks (-1.08; -1.80 to -0.36), and 6 months (-0.84; -1.37 to -0.30) after treatment. Psilocybin was associated with transient elevation in systolic (19.00; 13.58–24.41 mm Hg) and diastolic (8.66; 5.18–12.15 mm Hg) blood pressure compared with placebo. The differences between psilocybin and placebo groups with regard to allcause discontinuation, serious adverse events, and heart rates were nonsignificant.Conclusion Psilocybin-assisted therapy could ameliorate end-of-life anxiety symptoms without serious adverse events. Because of the small sample sizes of the included studies and high heterogeneity on long-term outcomes, future randomized controlled trials with large sample sizes are needed.
참고문헌 (45)
- Antoni MH, "Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer", Brain Behav Immun, 30(Suppl), pp.S88~S98 (2013)
- Gil F, "First anxiety, afterwards depression : psychological distress in cancer patients at diagnosis and after medical treatment", Stress Health, 28, pp.362~367 (2012)
- Linden W, "Anxiety and depression after cancer diagnosis : prevalence rates by cancer type, gender, and age", J Affect Disord, 141, pp.343~351 (2012)
- Perez MN, "Barriers to care in pediatric cancer : the role of illness uncertainty in relation to parent psychological distress", Psychooncology, 29, pp.304~310 (2020)
- Vander Haegen M, "Intolerance of uncertainty in parents of childhood cancer survivors : a clinical profile analysis", J Psychosoc Oncol, 36, pp.717~733 (2018)
- Sharpe L, "Fear of cancer recurrence and death anxiety", Psychooncology, 27, pp.2559~2565 (2018)
- Antoni MH, "The impact of psychosocial stress and stress management on immune responses in patients with cancer", Cancer, 125, pp.1417~1431 (2019)
- Antoni MH, "The influence of bio-behavioural factors on tumour biology : pathways and mechanisms", Nat Rev Cancer, 6, pp.240~248 (2006)
- O’Brien KK, "Exploring disability from the perspective of adults living with HIV", AIDS : development of a conceptual framework, 2008, pp.6, 76~
- O’Brien KK, "How do existing HIV-specific instruments measure up? Evaluating the ability of instruments to describe disability experienced by adults living with HIV", Health Qual Life Outcomes, 8, pp.88~ (2010)
- Logie C, "Meta-analysis of health and demographic correlates of stigma towards people living with HIV", AIDS Care, 21, pp.742~753 (2009)
- Basu S, "Clinical management of depression and anxiety in HIV-infected adults", AIDS, 19, pp.2057~2067 (2005)
- Nanni MG, "Depression in HIV infected patients : a review", Curr Psychiatry Rep, 17, pp.530~ (2015)
- Houck MM, "Fundamentals of Forensic Science", pp.315~352 (2015), Academic Press
- Vollenweider FX, "The neurobiology of psychedelic drugs : implications for the treatment of mood disorders", Nat Rev Neurosci, 11, pp.642~651 (2010)
- Griffiths R, "Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later", J Psychopharmacol, 22, pp.621~632 (2008)
- Griffiths RR, "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects", Psychopharmacology(Berl), 218, pp.649~665 (2011)
- Johnson MW, "Potential therapeutic effects of psilocybin", Neurotherapeutics, 14, pp.734~740 (2017)
- de Veen BT, "Psilocybin for treating substance use disorders?", Expert Rev Neurother, 17, pp.203~212 (2017)
- Grassi L, "Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care : a review", Int Rev Psychiatry, 26, pp.44~62 (2014)
- Heissel A, "Effects of exercise on depression and anxiety in persons living with HIV : a meta-analysis", J Psychosom Res, 126, pp.109823~ (2019)
- Breitbart W, "Meaning-centered group psychotherapy for patients with advanced cancer : a pilot randomized controlled trial", Psychooncology, 19, pp.21~28 (2010)
- Griffiths RR, "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : a randomized double-blind trial", J Psychopharmacol, 30, pp.1181~1197 (2016)
- Anderson BT, "Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men : an open-label safety and feasibility pilot study", EClinicalMedicine, 27, pp.100538~ (2020)
- Horikawa M, "The relationships among trait anxiety, state anxiety and the goal performance of penalty shoot-out by university soccer players", PLoS One, 7, pp.e35727~ (2012)
- Sterne JAC, "RoB 2: a revised tool for assessing risk of bias in randomised trials", BMJ, 366, pp.l4898~ (2019)
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
- Grob CS, "Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer", Arch Gen Psychiatry, 68, pp.71~78 (2011)
- Ross S, "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial", J Psychopharmacol, 30, pp.1165~1180 (2016)
- Agin-Liebes GI, "Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer", J Psychopharmacol, 34, pp.155~166 (2020)
- Onieva-Zafra MD, "Anxiety, perceived stress and coping strategies in nursing students : a cross-sectional, correlational, descriptive study", BMC Med Educ, 20, pp.370~ (2020)
- Silva AVD, "Anxiety and coping in women with breast cancer in chemotherapy", Rev Lat Am Enfermagem, 25, pp.e2891~ (2017)
- Erritzoe D, "Effects of psilocybin therapy on personality structure", Acta Psychiatr Scand, 138, pp.368~378 (2018)
- Nichols DE, "Psychedelics", Pharmacol Rev, 68, pp.264~355 (2016)
- Nic Dhonnchadha BA, "Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice", Behav Brain Res, 147, pp.175~184 (2003)
- Ripoll N, "Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice", Behav Brain Res, 166, pp.131~139 (2006)
- Ripoll N, "The four-plates test-retest paradigm to discriminate anxiolytic effects", Psychopharmacology(Berl), 180, pp.73~83 (2005)
- Carhart-Harris RL, "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin", Proc Natl Acad Sci U S A, 109, pp.2138~2143 (2012)
- Simmons A, "Anxiety vulnerability is associated with altered anterior cingulate response to an affective appraisal task", Neuroreport, 19, pp.1033~1037 (2008)
- Straube T, "Dynamic activation of the anterior cingulate cortex during anticipatory anxiety", Neuroimage, 44, pp.975~981 (2009)
- Shang J, "The common traits of the ACC and PFC in anxiety disorders in the DSM-5 : meta-analysis of voxel-based morphometry studies", PLoS One, 9, pp.e93432~ (2014)
- Nichols DE, "Psychedelics as medicines : an emerging new paradigm", Clin Pharmacol Ther, 101, pp.209~219 (2017)
- Smit M, "Future challenges for clinical care of an ageing population infected with HIV : a modelling study", Lancet Infect Dis, 15, pp.810~818 (2015)
- Aronson JK, "Meyler’s Side Effects of Drugs", pp.1048~1051 (2016), Elsevier
- Johnson MW, "The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act", Neuropharmacology, 142, pp.143~166 (2018)